GeoVax Labs, Inc. (NASDAQ:GOVX - Get Free Report) CEO David A. Dodd acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average price of $1.08 per share, with a total value of $10,800.00. Following the completion of the transaction, the chief executive officer now owns 36,661 shares of the company's stock, valued at approximately $39,593.88. This trade represents a 37.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
GeoVax Labs Trading Up 1.9 %
Shares of GOVX opened at $1.08 on Wednesday. The stock has a market cap of $10.19 million, a P/E ratio of -0.19 and a beta of 3.06. GeoVax Labs, Inc. has a 1 year low of $1.03 and a 1 year high of $11.18. The stock's 50-day moving average price is $1.62 and its two-hundred day moving average price is $2.10.
GeoVax Labs (NASDAQ:GOVX - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.49. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $2.38 million. As a group, equities analysts forecast that GeoVax Labs, Inc. will post -4.49 EPS for the current year.
Hedge Funds Weigh In On GeoVax Labs
Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company's stock worth $223,000 after acquiring an additional 33,440 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the fourth quarter worth about $104,000. Virtu Financial LLC acquired a new stake in shares of GeoVax Labs during the third quarter worth about $97,000. Finally, Northern Trust Corp bought a new position in shares of GeoVax Labs during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 6.09% of the company's stock.
Analysts Set New Price Targets
Separately, D. Boral Capital reiterated a "buy" rating and set a $18.00 price target on shares of GeoVax Labs in a research report on Friday, March 28th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, GeoVax Labs has a consensus rating of "Buy" and a consensus price target of $14.20.
Check Out Our Latest Research Report on GeoVax Labs
About GeoVax Labs
(
Get Free Report)
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
